Roka Bioscience Inc (NASDAQ:ROKA) has been assigned a consensus broker rating score of 1.00 (Strong Buy) from the one analysts that provide coverage for the stock, Zacks Investment Research reports.
Zacks has also given Roka Bioscience an industry rank of 136 out of 265 based on the ratings given to related companies.
Separately, Roth Capital assumed coverage on Roka Bioscience in a report on Monday, December 12th. They issued a “buy” rating and a $10.00 target price for the company.
Shares of Roka Bioscience (NASDAQ:ROKA) opened at 4.40 on Friday. Roka Bioscience has a 1-year low of $0.50 and a 1-year high of $7.37. The company’s market cap is $8.10 million. The stock has a 50 day moving average price of $4.49 and a 200-day moving average price of $2.93.
Roka Bioscience (NASDAQ:ROKA) last issued its earnings results on Monday, November 7th. The company reported ($5.39) earnings per share (EPS) for the quarter. Roka Bioscience had a negative return on equity of 89.22% and a negative net margin of 487.61%. The company earned $1.90 million during the quarter, compared to analyst estimates of $1.50 million. Analysts predict that Roka Bioscience will post ($17.24) earnings per share for the current fiscal year.
About Roka Bioscience
Roka Bioscience, Inc is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.
Get a free copy of the Zacks research report on Roka Bioscience (ROKA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com